July 17, 2017 / 8:55 PM / a month ago

BRIEF-FDA approves Puma Biotech's new treatment to reduce risk of breast cancer returning

July 17 (Reuters) - Puma Biotechnology Inc

* U.S. Food and Drug Administration - approved Nerlynx (neratinib) for the extended adjuvant treatment of early-stage, her2-positive breast cancer

* U.S. FDA says granted the approval of Nerlynx to Puma Biotechnology Inc Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below